Rivaroxaban for prevention and treatment of venous thromboembolism

被引：9
|
作者：
Chan, Noel C. [1 ,2 ]
Weitz, Jeffrey, I [1 ,2 ]
机构：
[1] McMaster Univ, Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada
[2] McMaster Univ, Dept Med, Hamilton, ON, Canada
来源：
FUTURE CARDIOLOGY | 2019年 / 15卷 / 02期
关键词：
nonvitamin K oral antagonist; rivaroxaban; venous thromboembolism; FACTOR-XA INHIBITOR; DIRECT ORAL ANTICOAGULANTS; DEEP-VEIN THROMBOSIS; TOTAL HIP; ORTHOPEDIC-SURGERY; EXTENDED TREATMENT; KNEE REPLACEMENT; REAL-WORLD; ENOXAPARIN; THROMBOPROPHYLAXIS;
D O I：
10.2217/fca-2018-0076
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Until recently, heparins and vitamin K antagonists (VKAs) were the cornerstones for prevention and treatment of venous thromboembolism (VTE). This situation changed with the introduction of the direct oral anticoagulants, which are now replacing low-molecular-weight heparin for thromboprophylaxis after elective hip or knee arthroplasty and VKAs for VTE treatment. Rivaroxaban, an oral factor Xa inhibitor, was the first direct oral anticoagulant licensed for VTE prevention and treatment. This paper provides the rationale for factor Xa as a target for anticoagulants, describes the development of rivaroxaban, reviews its pharmacological profile, discusses the clinical trials with rivaroxaban for VTE prevention and treatment and highlights areas of uncertainty.
引用
收藏
页码：63 / 77
页数：15
相关论文
共 50 条
  • [1] Rivaroxaban for the prevention and treatment of venous thromboembolism
    Turpie, Alexander G. G.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 (01) : 33 - 38
  • [2] Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban
    Bauersachs, Rupert
    Khorana, Alok A.
    Lee, Agnes Y. Y.
    Soff, Gerald
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2020, 4 (04) : 532 - 549
  • [3] Rivaroxaban in the Treatment of Venous Thromboembolism and the Prevention of Recurrences: A Practical Approach
    Arcelus, Juan I.
    Domenech, Pere
    del Carmen Fernandez-Capitan, Ma
    Guijarro, Ricardo
    Jimenez, David
    Jimenez, Sonia
    Lozano, Francisco S.
    Monreal, Manel
    Nieto, Jose A.
    Paramo, Jose A.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2015, 21 (04) : 297 - 308
  • [4] Rivaroxaban in the treatment of venous thromboembolism
    Pruszczyk, Piotr
    KARDIOLOGIA POLSKA, 2012, 70 (09) : 976 - 976
  • [5] Rivaroxaban for the treatment of venous thromboembolism The SWISS Venous ThromboEmbolism Registry (SWIVTER)
    Kucher, Nils
    Aujesky, Drahomir
    Beer, Jurg H.
    Mazzolai, Lucia
    Baldi, Thomas
    Banyai, Martin
    Hayoz, Daniel
    Kaeslin, Thomas
    Korte, Wolfgang
    Escher, Robert
    Husmann, Marc
    Frauchiger, Beat
    Baumgartner, Iris
    Spirk, David
    THROMBOSIS AND HAEMOSTASIS, 2016, 116 (03) : 472 - 479
  • [6] Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism
    Coleman, Craig I.
    Bunz, Thomas J.
    Turpie, Alexander G. G.
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (10) : 1841 - 1847
  • [7] Prevention of venous thromboembolism with rivaroxaban and apixaban in orthopedic surgery
    Antonijevic, Nebojsa
    Kanjuh, Vladimir
    Zivkovic, Ivana
    Jovanovic, Ljubica
    Vukcevic, Miodrag
    Apostolovic, Milan
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2020, 148 (9-10) : 613 - 620
  • [8] Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal
    Stevenson, M.
    Scope, A.
    Holmes, M.
    Rees, A.
    Kaltenthaler, E.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 43 - 48
  • [9] Practical Management of Rivaroxaban for the Treatment of Venous Thromboembolism
    Imberti, Davide
    Benedetti, Raffaella
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2015, 21 (04) : 309 - 318
  • [10] Apixaban or rivaroxaban in the treatment of acute venous thromboembolism?
    Hellfritzsch, Maja
    Grove, Erik L.
    Adelborg, Kasper
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
12345